GlassScriptPhysician profile
Ravi K Koduru
NPI 1265521058
$8,121.02
in general payments reported to CMS, 2019-2025
53 companies · $922 in 2025
The $922 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,112 · 2020: $852 · 2021: $1,491 · 2022: $528 · 2023: $1,096 · 2024: $1,119 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,137.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $944.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $913.65 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Lilly USA, LLC | $658.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $655.19 | 2019-2025 | |
| Abbvie INC. | $608.86 | 2019-2025 | |
| Amgen INC. | $591.72 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $395.38 | 2019-2025 | |
| Glaxosmithkline, LLC. | $363.60 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $187.44 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.98 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $175.83 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $171.66 | 2019-2021 | |
| Antares Pharma, INC. | $159.37 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Janssen Pharmaceuticals, INC | $152.47 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $135.59 | 2020-2021 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Koduru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.